Abstract Number: 138 • 2012 ACR/ARHP Annual Meeting
Evaluating Appropriate Use of Prophylactic Colchicine and Urate Lowering Therapy in Gout
Background/Purpose: Colchicine is recommended to prevent gout flares in patients initiating and increasing uric acid lowering therapy until serum uric acid is ≤ 6 mg/dL.…Abstract Number: 1902 • 2012 ACR/ARHP Annual Meeting
What Factors Are Associated with Target Serum Urate Concentrations in Patients with Gout?
Background/Purpose: Long term serum urate (SU) lowering to a target ofAbstract Number: 1628 • 2012 ACR/ARHP Annual Meeting
Epistatic Interaction Between Solute Carrier 2A9 Genotype and Sugar-Sweetened Beverage Consumption in the Determination of Gout Risk
Background/Purpose: Consumption of drinks sweetened with sugar or high fructose corn syrup increases both serum urate levels and the risk for gout. SLC2A9 encodes a…Abstract Number: 1630 • 2012 ACR/ARHP Annual Meeting
Genetic Variants of Serum Uric Acid and Gout: An Analysis of > 170,000 Individuals
Background/Purpose: Gout is a common and excruciatingly painful inflammatory arthritis caused by hyperuricemia. In addition to various lifestyle risk factors, a substantial genetic predisposition to…Abstract Number: 818 • 2012 ACR/ARHP Annual Meeting
Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Background/Purpose: The investigational new drug levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative approved in over 20 countries outside the US for treatment…
- « Previous Page
- 1
- …
- 3
- 4
- 5